@article{ff5510b298fc408dad49cd9400555091,
title = "Considerations for performing level-2 centiloid transformations for amyloid PET SUVR values",
abstract = "The Centiloid Project describes a post-hoc data transformation to standardize amyloid PET measurements to enable direct data comparisons across sites and studies using differing acquisition/analysis methods. It uses linear regression that transforms values using different measurement scales to match those from a standard Centiloid unit scale. Our group's measurement method differs from the Centiloid's standard method in both acquisition and analysis methods. In this work we examine multiple variations for performing these transformations and compare several approaches. We hypothesized that using Deming regression, which accounts for error on both axes, would produce a more optimal transformation than the recommended standard linear regression. We also examined the effects of performing separate regressions for differences in acquisition and analysis methods, rather than a direct single-regression approach. Our results found that all transformation approaches had very similar performance and were within the recommended tolerance thresholds.",
author = "Schwarz, {Christopher G.} and Nirubol Tosakulwong and Senjem, {Matthew L.} and Gunter, {Jeffrey L.} and Therneau, {Terry M.} and Prashanthi Vemuri and Lowe, {Val J.} and Jack, {Clifford R.}",
note = "Funding Information: The authors would like to thank William E. Klunk and Robbert A. Koeppe for their prompt and detailed clarifications provided during this work. The authors would also like to thank these funding sources: NIH R01 AG011378, R01 AG041851, and the Alexander Family Alzheimer{\textquoteright}s Disease Research Professorship of the Mayo Clinic. Funding Information: Competing Interests: Christopher Schwarz receives research funding from the NIH. Nirubol Tosakulwong reports no disclosures. Matthew Senjem holds stock in Align Technology, Inc., Gilead Sciences, Inc., Globus Medical Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, LHC Group, Inc., Medtronic, Mesa Laboratories, Inc., Natus Medical Incorporated, Varex Imaging Corporation. Jeffrey Gunter reports no disclosures. Terry Therneau reports no disclosures. Prashanthi Vemuri is funded by the NIH. Val Lowe consults for Bayer Schering Pharma, Piramal Life Sciences and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals and the NIH (NIA, NCI). Clifford Jack has provided consulting services for Eli Lily. He receives research funding from the NIH (R01-AG011378, U01-AG024904, RO1 AG041851, R01 AG37551, R01AG043392, U01-AG06786), and the Alexander Family Alzheimer{\textquoteright}s Disease Research Professorship of the Mayo Clinic. Publisher Copyright: {\textcopyright} 2018 The Author(s).",
year = "2018",
month = dec,
day = "1",
doi = "10.1038/s41598-018-25459-9",
language = "English (US)",
volume = "8",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",
}